Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Contineum Therapeutics, Inc.CTNM · Entity 5311 | Director | June 26, 2026 | June 26, 2026 |
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | Director | April 02, 2026 | April 06, 2026 |
| Karuna Therapeutics, Inc.KRTX · Entity 92934 | Chief Financial Officer | August 22, 2023 | August 24, 2023 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Chief Financial Officer | February 02, 2026 | February 04, 2026 |
| scPharmaceuticals Inc.SCPH · Entity 74456 | Chief Financial Officer | January 17, 2018 | January 19, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Contineum Therapeutics, Inc.
Report date June 26, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.19 · Expires 2036-06-25 | Direct | 19,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 19,000 · Balance 19,000 F1: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.
Harmony Biosciences Holdings, Inc.
Report date April 02, 2026 · Filed April 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $27.74 · Expires 2036-04-02 | Direct | 17,710 |
Reported balance
After 2026-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-02 · Grant · Acquired 17,710 · Balance 17,710 F1: The stock option shall vest in 36 equal monthly installments beginning on May 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest in 36 equal monthly installments beginning on May 2, 2026.
Karuna Therapeutics, Inc.
Report date August 22, 2023 · Filed August 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,487 |
Ending reported balance
After 2023-08-22 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2023-08-22 · Exercise / conversion · Acquired 1,500 · Balance 31,987 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. Row 2 · 2023-08-22 · Sale · Disposed 80 · Balance 31,907 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.31 to $174.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (5) to this Form 4. Row 3 · 2023-08-22 · Sale · Disposed 855 · Balance 31,052 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.32 to $175.31, inclusive. Row 4 · 2023-08-22 · Sale · Disposed 505 · Balance 30,547 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.32 to $176.30, inclusive. Row 5 · 2023-08-22 · Sale · Disposed 60 · Balance 30,487 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.59 to $176.61, inclusive. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 · Expires 2029-03-21 | Direct | 93,226 |
Reported balance
After 2023-08-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-08-22 · Exercise / conversion · Disposed 1,500 · Balance 93,226 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F6: This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.31 to $174.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (5) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.32 to $175.31, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.32 to $176.30, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.59 to $176.61, inclusive.
F6: This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter.
Rapport Therapeutics, Inc.
Report date February 02, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.75 · Expires 2036-02-02 | Direct | 148,000 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 148,000 · Balance 148,000 F1: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.
scPharmaceuticals Inc.
Report date January 17, 2018 · Filed January 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.23 · Expires 2028-01-17 | Direct | 42,616 |
Reported balance
After 2018-01-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-17 · Grant · Acquired 42,616 · Balance 42,616 F1: The option shares vest over a four-year period, at a rate of 25% on the first anniversary of the grant date, with the remaining option shares vesting in 36 equal monthly installments thereafter, such that the option shares are fully vested on the fourth anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares vest over a four-year period, at a rate of 25% on the first anniversary of the grant date, with the remaining option shares vesting in 36 equal monthly installments thereafter, such that the option shares are fully vested on the fourth anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CinCor Pharma, Inc.
Report date February 24, 2023 · Filed February 24, 2023
Section 16 reporting ended · disclosed 2023-02-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.82 · Expires 2031-06-17 | Direct | 0 |
Reported balance
After 2023-02-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-24 · Disposition to issuer · Disposed 36,324 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 · Expires 2031-12-09 | Direct | 0 |
Reported balance
After 2023-02-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-24 · Disposition to issuer · Disposed 58,823 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2020 Filed May 12, 2020 20:33 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 7,500 | $83.38 | $625,350.00 |
DisclosureSEC source: 0001593968-20-001152 · primary_01.xml · nonDerivative · entry 2 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:33 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 7,500 | $9.20 | $69,000.00 |
DisclosureSEC source: 0001593968-20-001152 · primary_01.xml · nonDerivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:42 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 7,500 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0001593968-20-000623 · primary_01.xml · derivative · entry 3 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,294 Underlying: Karuna Therapeutics, Inc. Common Stock · 7,500 shares Expires 2029-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:42 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 7,500 | $86.50 | $648,750.00 |
DisclosureSEC source: 0001593968-20-000623 · primary_01.xml · nonDerivative · entry 2 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:42 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 7,500 | $9.20 | $69,000.00 |
DisclosureSEC source: 0001593968-20-000623 · primary_01.xml · nonDerivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:30 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $99.72 | $0.00 |
DisclosureSEC source: 0000899243-20-005042 · doc4.xml · derivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-02-14 F1 · derivative.exercise_date: 25% of the options shall vest on February 14, 2021, and the remaining options shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates. Read SEC document |
| January 17, 2018 Filed Jan 19, 2018 16:27 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 42,616 | $0.00 Strike: $12.23 | $0.00 |
DisclosureSEC source: 0000899243-18-001525 · doc4.xml · derivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,616 Underlying: Common Stock · 42,616 shares Expires 2028-01-17 F1 · derivative.exercise_date: The option shares vest over a four-year period, at a rate of 25% on the first anniversary of the grant date, with the remaining option shares vesting in 36 equal monthly installments thereafter, such that the option shares are fully vested on the fourth anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.